Global X China Biotech ETF

2820 HKD
9820 USD

Invest in 2820 /9820

Important Information

Investors should not base investment decisions on this website alone. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. There is no guarantee of the repayment of the principal. Investors should note:

  • Global X China Biotech ETF’s (the “Fund’s”) investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors, such as changes in investment sentiment, political and economic conditions and issuer-specific factors.
  • Biotech companies invest heavily in research and development which may not necessarily lead to commercially successful products, and the ability for biotech companies to obtain regulatory approval (for example, product approval) may be long and costly.
  • China is an emerging market. The Fund invests in Chinese companies which may involve increased risks and special considerations not typically associated with investments in more developed markets, such as liquidity risk, currency risks, political risk, legal and taxation risks, and the likelihood of a high degree of volatility.
  • The trading price of the Fund’s unit (the “Unit”) on the Stock Exchange of Hong Kong is driven by market factors such as demand and supply of the Unit. Therefore, the Units may trade at a substantial premium or discount to the Fund’s net asset value.
  • The Fund’s synthetic replication strategy will involve investing up to 50% of its net asset value in financial derivative instruments (“FDIs”), mainly funded total return swap transaction(s) through one or more counterparty(ies). Risks associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. FDIs are susceptible to price fluctuations and higher volatility, and may have large bid and offer spreads and no active secondary markets. The leverage element/component of an FDI can result in a loss significantly greater than the amount invested in the FDI by the Sub-Fund.
  • As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund. The borrower may fail to return the securities in a timely manner or at all. The Fund may suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund’s ability in meeting delivery or payment obligations from realisation requests.

Why Invest ?

High Growth Potential

Global X China Biotech ETF enables investors to access high growth potential through companies critical to the development of biotechnology in China.

Targeted Exposure

The fund delivers targeted exposure to an emerging theme and industry.

ETF Efficiency

In a single trade, the fund delivers access to dozens of companies with high exposure to the biotech theme in China.

Fund InformationAs of 28 Sep 2023

Fund Inception Date 24 Jul 2019
SEHK Listing Date 25 Jul 2019
Fiscal Year Ending 31 Mar
Ongoing Charges Over A Year ^ 0.68%
Distribution Frequency Annually at the Manager's discretion (May in each year).
^ The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. Click to learn more.

Index Information 1 As of 28 Sep 2023

Underlying Index Solactive China Biotech Index NTR 2
Index Type Net Total Return
Base Currency RMB
Closing Level 1,558.47
Change -19.42
Change % -1.23%

ETF Summary

The Global X China Biotech ETF (2820/9820) seeks to invest in companies involved in the development of biotechnology in China, including companies whose principal business is in research, development, manufacturing, and distribution of new drugs, therapies, or vaccines using biological materials.

ETF Objective

The Fund is a passive ETF and seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR (the “Index”).

Trading InformationAs of 28 Sep 2023

Exchange Hong Kong Stock Exchange
Stock Code 2820
ISIN HK0000516697
Board Lot Size 50 Units
Trading Currency HKD
Total Net Asset Value $583,096,944.37
Outstanding Units 10,350,000

Near Real Time Estimated NAV per Unit4

-- $ -- $ --
-- $ -- $ --

* Market prices are provided on a 15-minute delayed basis by ICE Data Services. (See terms and conditions)

Daily NAV per Unit5As of 28 Sep 2023

NAV Change % Change
Official NAV per Unit in RMB $52.52 $-0.66 -1.23%
NAV per Unit in HKD 3 $56.34 $-0.70 -1.23%
NAV per Unit in USD3 $7.20 $-0.09 -1.23%

Performance As of 28 Sep 2023

Cumulative Return Fund NAV (%) Benchmark (%)
1 Mth 5.37 5.45
3 Mths 3.26 3.49
6 Mths -8.73 -8.41
1 Yr 2.25 3.04
YTD -11.72 -11.23
Since Inception 5.05 9.17
Calendar Year Return Fund NAV (%) Benchmark (%)
2022 -26.09 -25.52
2021 -19.65 -19.17
2020 69.70 71.88
2019^ 17.09 17.50
^ Since listing date to the end of the calendar year.
Source: Mirae Asset Global Investments (Hong Kong) Limited.
• Past performance information is not indicative of future performance. Investors may not get back the full amount invested.
• The computation basis of the performance is based on the calendar year end, NAV-to-NAV, with dividend reinvested.
• These figures show by how much the Sub-Fund increased or decreased in value during the calendar year shown.
• Performance data has been calculated in RMB including ongoing charges and excluding trading costs on SEHK you might have to pay.
• Where no past performance is shown there was insufficient data available in that year to provide performance.
• The Index of the Fund is Solactive China Biotech Index.
• The Fund launch date : 24 Jul 2019

Holdings Overview As of 28 Sep 2023

Total Net Asset Value (in HKD) Total Net Asset Value (in USD) Number of Securities Securities (%) Cash and Cash Equivalent (%)
583,096,944.37 74,486,112.92 38 99.95 0.05

Daily HoldingsAs of 28 Sep 2023

Name of Securities Exchange Ticker Exchange Market Price (in RMB) Number of Shares Held Market Value (in RMB) Net Assets (%)
WUXI APPTEC CO LTD 603259 C1 Shanghai 86.18 718,851 61,950,579.18 11.40
WUXI BIOLOGICS CAYMAN INC 2269 HK Hong Kong 41.12 1,296,264 53,298,068.99 9.80
JIANGSU HENGRUI PHARMACEUT 600276 C1 Shanghai 44.94 1,023,130 45,979,462.20 8.46
INNOVENT BIOLOGICS INC 1801 HK Hong Kong 37.20 1,076,258 40,037,662.43 7.36
SHANGHAI RAAS BLOOD PRODUC 002252 C2 Shenzhen 6.96 3,666,600 25,519,536.00 4.69
SINO BIOPHARMACEUTICAL 1177 HK Hong Kong 2.62 8,322,763 21,804,858.51 4.01
WALVAX BIOTECHNOLOGY CO 300142 C2 Shenzhen 23.54 874,000 20,573,960.00 3.78
BEIJING TIANTAN BIOLOGICAL 600161 C1 Shanghai 25.63 771,600 19,776,108.00 3.64
CHINA NATIONAL MEDICINES 600511 C1 Shanghai 33.15 512,800 16,999,320.00 3.13
GENSCRIPT BIOTECH CORP 1548 HK Hong Kong 19.49 853,876 16,638,743.18 3.06
AKESO INC 9926 HK Hong Kong 35.34 434,738 15,361,946.15 2.83
ZAI LAB LTD-ADR ZLAB US New York 175.16 85,099 14,906,113.15 2.74
GAN & LEE PHARMACEUTICALS 603087 C1 Shanghai 45.12 310,000 13,987,200.00 2.57
SHENZHEN KANGTAI BIOLOGICA 300601 C2 Shenzhen 29.27 465,700 13,631,039.00 2.51
SHANGHAI JUNSHI BIOSCIENCE 688180 C1 Shanghai 38.50 350,800 13,505,800.00 2.48
CHINA MEDICAL SYSTEM HOLDING 867 HK Hong Kong 11.00 1,133,131 12,466,414.24 2.29
LIVZON PHARMACEUTICAL GROU 000513 C2 Shenzhen 36.94 335,700 12,400,758.00 2.28
BETTA PHARMACEUTICALS CO L 300558 C2 Shenzhen 57.28 203,000 11,627,840.00 2.14
HYGEIA HEALTHCARE HOLDINGS C 6078 HK Hong Kong 40.32 281,193 11,338,876.95 2.09
HUALAN BIOLOGICAL ENGINEER 002007 C2 Shenzhen 22.20 472,300 10,485,060.00 1.93
HANSOH PHARMACEUTICAL GROUP 3692 HK Hong Kong 9.79 961,905 9,416,747.09 1.73
BGI GENOMICS CO LTD 300676 C2 Shenzhen 52.17 179,200 9,348,864.00 1.72
HUBEI JUMPCAN PHARMACEUT 600566 C1 Shanghai 27.34 328,200 8,972,988.00 1.65
ZHEJIANG WOLWO BIO-PHARMAC 300357 C2 Shenzhen 29.75 258,100 7,678,475.00 1.41
HUALAN BIOLOGICAL ENGINEER 002007 C2 Shenzhen 22.20 339,000 7,525,800.00 1.38
APELOA PHARMACEUTICAL CO 000739 C2 Shenzhen 17.99 372,000 6,692,280.00 1.23
WALVAX BIOTECHNOLOGY CO 300142 C2 Shenzhen 23.54 275,400 6,482,916.00 1.19
REMEGEN CO LTD 688331 C1 Shanghai 61.53 81,500 5,014,695.00 0.92
NANJING KING-FRIEND BIOCHE 603707 C1 Shanghai 12.69 386,200 4,900,878.00 0.90
SHANGHAI JUNSHI BIOSCIENCE 688180 C1 Shanghai 38.50 117,499 4,523,711.50 0.83
BETTA PHARMACEUTICALS CO L 300558 C2 Shenzhen 57.28 64,500 3,694,560.00 0.68
SIMCERE PHARMACEUTICAL GROUP 2096 HK Hong Kong 5.98 560,981 3,352,629.85 0.62
GAN & LEE PHARMACEUTICALS 603087 C1 Shanghai 45.12 69,200 3,122,304.00 0.57
BEIJING WANTAI BIOLOGICAL 603392 C1 Shanghai 47.98 49,800 2,389,404.00 0.44
APELOA PHARMACEUTICAL CO 000739 C2 Shenzhen 17.99 125,100 2,250,549.00 0.41
BGI GENOMICS CO LTD 300676 C2 Shenzhen 52.17 42,862 2,236,110.54 0.41
3D MEDICINES INC 1244 HK Hong Kong 15.70 118,093 1,854,153.43 0.34
REMEGEN CO LTD 688331 C1 Shanghai 61.53 26,075 1,604,394.75 0.30
Holdings are subject to change. Cash, where shown, includes other assets and liabilities, such as payables and receivables.

Tracking Difference / Error

Tracking Difference / Tracking Error

Tracking Difference
Tracking difference is the return difference between the Fund and the Underlying Index over a certain period of time.
Tracking Error
Tracking error measures how consistently the Fund follows the Underlying Index. It is the volatility (measured by standard deviation) of that return difference.

Tracking Difference (TD)

Fund Listing Date:25 Jul 2019

Rolling 1 Year TD: N/A

TD for Calendar Year 2022:-0.57%

TD for Calendar Year 2021:-0.48%

TD for Calendar Year 2020:-2.18%

Tracking Error (TE)

Fund Listing Date:25 Jul 2019

Rolling 1 Year TE^ :N/A%

^ Annualized based on the number of dealing days in the past year when daily TD is calculated.

Graph for Tracking Difference

ETFs performance is calculated on an NAV to NAV basis and assumes reinvestment of distribution.

Hover over the chart points for details

Market Makers 6

Flow Traders Hong Kong Limited

Mirae Asset Securities Co., Ltd.

Optiver Trading Hong Kong Limited

Participating Dealers 7

China Merchants Securities (HK) Co., Limited

ABN AMRO Clearing Hong Kong Ltd

Haitong International Securities Company Limited

Mirae Asset Securities (HK) Limited

Yuanta Securities (Hong Kong) Company Limited

Citigroup Global Markets Asia Limited

Barclays Bank PLC

SinoPac Securities (Asia) Limited

Key Documents

Monthly Returns

Announcements / Notices

Back to Top

You’re now leaving Global X Hong Kong website

Clicking "Confirm" below will take you to an independent site. Information and services provided on this independent site are not reviewed by, guaranteed by, or Global X Hong Kong. This independent site's terms and conditions, privacy and security policies, or other legal information may be different from those of Global X Hong Kong’s site. Global X Hong Kong is not liable for any direct or indirect technical or system issues, consequences, or damages arising from your use of this independent website.


This website is intended for Hong Kong investors only. Your use of this website means you agree to our Terms of use. This website is strictly for informational purposes only and does not constitute a representation that any investment strategy is suitable or appropriate for an investor’s individual circumstances. In 2018, Global X was acquired by Mirae Asset Global Investments and Mirae Asset Global Investments Co., Ltd. is the parent company of Mirae Asset Global Investments (Hong Kong) Limited.

The information contained in this website is for information purposes only and does not, constitute any recommendations, offer or solicitation to buy, sell or subscribe to any securities or financial instruments in any jurisdiction. Investment involves risk. It cannot be guaranteed that the performance of the Product will generate a return and there may be circumstances where no return is generated or the amount invested is lost. Past performance is not indicative of future performance.

Before making any investment decision to invest in the Product, investors should read the Product’s prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Product and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investments.

Certain information contained in this website is compiled from third party sources. Whilst Mirae Asset Global Investments (Hong Kong) Limited (“Mirae Asset HK”), the Manager of the Product, has, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. Mirae Asset HK accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.

The Products are not sponsored, endorsed, issued, sold or promoted by their index providers. For details of an index provider including any disclaimer, please refer to the relevant Product’s offering documents.

The contents of this website is prepared and maintained by Mirae Asset Global Investments (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.